Jeffrey T Parsons1, H Jonathon Rendina, Jonathan M Lassiter, Thomas H F Whitfield, Tyrel J Starks, Christian Grov. 1. *Center for HIV/AIDS Educational Studies & Training, Hunter College of the City University of New York (CUNY), New York, NY; †Health Psychology and Clinical Science Doctoral Program, The Graduate Center of the City University of New York (CUNY), New York, NY; ‡Department of Psychology, Hunter College of the City University of New York (CUNY), New York, NY; and §CUNY Graduate School of Public Health and Health Policy, New York, NY.
Abstract
OBJECTIVES: The HIV care cascade provides milestones to track the progress of HIV-positive people from seroconversion through viral suppression. We propose a Motivational pre-exposure prophylaxis (PrEP) Cascade involving 5 stages based on the Transtheoretical Model of Change. METHODS: We analyzed data from 995 men in One Thousand Strong, a longitudinal study of a national panel of HIV-negative gay and bisexual men in the United States. RESULTS: Nearly all (89%) participants were sexually active in the past 3 months and 65% met Centers for Disease Control criteria for PrEP candidacy. Of those identified as appropriate candidates, 53% were Precontemplative (stage 1; unwilling to take or believing they were inappropriate candidates for PrEP) and 23% were in Contemplation (stage 2; willing and self-identified as appropriate candidates). Only 11% were in PrEParation (stage 3; seeing PrEP as accessible and planning to initiate PrEP) and 4% were in PrEP Action (stage 4; prescribed PrEP). Although few of those who were identified as appropriate candidates were on PrEP, nearly all PrEP users (98%) reported adhering to 4 or more doses per week and most (72%) were returning for recommended quarterly medical visits, resulting in 9% of PrEP candidates reaching Maintenance and Adherence (stage 5). CONCLUSIONS: The large majority of participants were appropriate candidates for PrEP, yet fewer than 1 in 10 were using and adherent to PrEP. These findings highlight the need for interventions tailored to address the unique barriers men face at each stage of the cascade, particularly at the earliest stages where the most dramatic losses were identified.
OBJECTIVES: The HIV care cascade provides milestones to track the progress of HIV-positive people from seroconversion through viral suppression. We propose a Motivational pre-exposure prophylaxis (PrEP) Cascade involving 5 stages based on the Transtheoretical Model of Change. METHODS: We analyzed data from 995 men in One Thousand Strong, a longitudinal study of a national panel of HIV-negative gay and bisexual men in the United States. RESULTS: Nearly all (89%) participants were sexually active in the past 3 months and 65% met Centers for Disease Control criteria for PrEP candidacy. Of those identified as appropriate candidates, 53% were Precontemplative (stage 1; unwilling to take or believing they were inappropriate candidates for PrEP) and 23% were in Contemplation (stage 2; willing and self-identified as appropriate candidates). Only 11% were in PrEParation (stage 3; seeing PrEP as accessible and planning to initiate PrEP) and 4% were in PrEP Action (stage 4; prescribed PrEP). Although few of those who were identified as appropriate candidates were on PrEP, nearly all PrEP users (98%) reported adhering to 4 or more doses per week and most (72%) were returning for recommended quarterly medical visits, resulting in 9% of PrEP candidates reaching Maintenance and Adherence (stage 5). CONCLUSIONS: The large majority of participants were appropriate candidates for PrEP, yet fewer than 1 in 10 were using and adherent to PrEP. These findings highlight the need for interventions tailored to address the unique barriers men face at each stage of the cascade, particularly at the earliest stages where the most dramatic losses were identified.
Authors: Ronald A Brooks; Raphael J Landovitz; Rachel L Kaplan; Eli Lieber; Sung-Jae Lee; Thomas W Barkley Journal: AIDS Patient Care STDS Date: 2011-12-07 Impact factor: 5.078
Authors: H Jonathon Rendina; Thomas H F Whitfield; Christian Grov; Tyrel J Starks; Jeffrey T Parsons Journal: Soc Sci Med Date: 2016-11-18 Impact factor: 4.634
Authors: Christoph D Spinner; Christoph Boesecke; Alexander Zink; Heiko Jessen; Hans-Jürgen Stellbrink; Jürgen Kurt Rockstroh; Stefan Esser Journal: Infection Date: 2015-10-15 Impact factor: 3.553
Authors: Julia L Marcus; Jonathan E Volk; Jess Pinder; Albert Y Liu; Oliver Bacon; C Bradley Hare; Stephanie E Cohen Journal: Curr HIV/AIDS Rep Date: 2016-04 Impact factor: 5.071
Authors: Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant Journal: Sci Transl Med Date: 2012-09-12 Impact factor: 17.956
Authors: George Ayala; Keletso Makofane; Glenn-Milo Santos; Jack Beck; Tri D Do; Pato Hebert; Patrick A Wilson; Thomas Pyun; Sonya Arreola Journal: J Sex Transm Dis Date: 2013-07-08
Authors: Heather Bradley; H Irene Hall; Richard J Wolitski; Michelle M Van Handel; Amy E Stone; Michael LaFlam; Jacek Skarbinski; Darrel H Higa; Joseph Prejean; Emma L Frazier; Roshni Patel; Ping Huang; Qian An; Ruiguang Song; Tian Tang; Linda A Valleroy Journal: MMWR Morb Mortal Wkly Rep Date: 2014-11-28 Impact factor: 17.586
Authors: Meredith E Clement; Barbara E Johnston; Cedar Eagle; Destry Taylor; Anna Lina Rosengren; Benjamin A Goldstein; Arlene C Seña Journal: AIDS Patient Care STDS Date: 2019-06-24 Impact factor: 5.078
Authors: Tiara C Willie; Jamila K Stockman; Danya E Keene; Sarah K Calabrese; Kamila A Alexander; Trace S Kershaw Journal: J Acquir Immune Defic Syndr Date: 2019-04-01 Impact factor: 3.731
Authors: Robert C Bollinger; Chloe L Thio; Mark S Sulkowski; Jane McKenzie-White; David L Thomas; Charles Flexner Journal: Lancet HIV Date: 2019-12-20 Impact factor: 12.767
Authors: Michael E Newcomb; Kevin Moran; Brian A Feinstein; Emily Forscher; Brian Mustanski Journal: J Acquir Immune Defic Syndr Date: 2018-04-01 Impact factor: 3.731
Authors: Patrick S Sullivan; Robertino Mera Giler; Farah Mouhanna; Elizabeth S Pembleton; Jodie L Guest; Jeb Jones; Amanda D Castel; Howa Yeung; Michael Kramer; Scott McCallister; Aaron J Siegler Journal: Ann Epidemiol Date: 2018-06-22 Impact factor: 3.797
Authors: Evan A Krueger; Ian W Holloway; Marguerita Lightfoot; Andy Lin; Phillip L Hammack; Ilan H Meyer Journal: LGBT Health Date: 2020-04-16 Impact factor: 4.151
Authors: Kellie Schueler; Matthew Ferreira; Georgios Nikolopoulos; Britt Skaathun; Dimitrios Paraskevis; Angelos Hatzakis; Samuel R Friedman; John A Schneider Journal: AIDS Behav Date: 2019-07
Authors: Christian Grov; Alexa B D'Angelo; Anthony W P Flynn; Javier Lopez-Rios; David W Pantalone; Ian W Holloway; Thomas H F Whitfield; Jeffrey T Parsons Journal: AIDS Educ Prev Date: 2018-08